Pharmacokinetic Features and Clinical Status
Traditionally, many drugs for severe joint pathologies require parenteral administration, but auranofin (Auranofinum) is designed for oral administration (per os). This makes it more convenient for outpatient use, but this is where its pharmacokinetic advantages end.
The main clinical feature of gold compounds is their extremely long latent period. Following the initiation of regular therapy, the therapeutic effect develops very slowly. The patient and physician typically must wait four to six months on average before the first objective signs of reduced inflammatory activity and joint pain relief become noticeable.
Because of this delayed onset and the emergence of safer alternatives, the clinical status of the drug has been heavily reconsidered. Today, auranofin is largely obsolete and absent from standard clinical formularies, precluding its routine medical use.
Mechanism of Action: How Gold Protects the Joint
The mechanism by which Auranofinum exerts its pharmacological action represents a sequential cascade of reactions aimed at suppressing the aggressive immune response directly within the site of inflammation.
- Penetration into the joint cavity. After gastrointestinal absorption, the active substance selectively migrates to affected joints, penetrating the synovial fluid.
- Phagocytosis by macrophages. Within the joint cavity, the drug encounters key inflammatory cells: macrophages. These cells actively engulf the gold compounds.
- Inhibition of cellular activity. Once inside the macrophage, the drug blocks phagocytosis. Furthermore, it specifically inhibits the activity of lysosomal enzymes—aggressive molecules that are released during autoimmune inflammation to destroy the body's own tissues.
- Reduction of destruction. This intracellular intervention results in a sharp drop in the destructive potential of macrophages. Inhibiting the release of lysosomal enzymes significantly slows down the destruction of cartilage and bone tissue in the joint.
Safety Profile and High Toxicity
The abandonment of widespread gold compound use in modern medicine is driven by their high toxicity. Side effects affect multiple vital organ systems simultaneously, making the therapy potentially hazardous.
- Hematologic toxicity: The drug can suppress hematopoiesis, clinically manifesting as severe anemia. Reduced erythrocyte levels lead to tissue hypoxia.
- Gastrointestinal tract injury: The mucosal linings of the digestive tract are extremely sensitive to gold compounds. Patients frequently develop stomatitis (painful inflammation of the oral mucosa) and enterocolitis (intestinal inflammation accompanied by digestive disturbances).
- Organotoxicity: The drug inflicts serious damage on major excretory and metabolic organs. Marked impairments in renal and hepatic functions are documented during therapy. The development of renal or hepatic failure is a life-threatening condition requiring immediate discontinuation of the drug.